Table 5.

Top 10 largest flow of co-cited references. The flow increases as the flow lines become thicker, reflecting the significance of the co-cited reference.

Rank	Article title	Author	Year	Flow
1	Evolocumab and clinical outcomes in patients with cardiovascular disease	Marc S. Sabatine	2017	0.0657
2	Efficacy and safety of alirocumab in reducing lipids and cardiovascular events	Jennifer G. Robinson	2015	0.0585
3	ODYSSEY FH I and FH II: 78 week results with alirocumab treatment in 735 patients with heterozygous familial hypercholesterolemia	John J.P. Kastelein	2015	0.0582
4	Efficacy and safety of alirocumab in high cardiovascular risk patients with inadequately controlled hypercholesterolemia on maximally tolerated doses of statins: the ODYSSEY COMBO II randomized controlled trial	Christopher P Cannon	2015	0.0519
5	Efficacy and safety of the proprotein convertase subtilisin/kexin type 9 inhibitor alirocumab among high cardiovascular risk patients on maximally tolerated statin therapy: The ODYSSEY COMBO I study	Dean J. Kereiakes	2015	0.0510
6	Alirocumab as add-on to atorvastatin versus other lipid treatment strategies: ODYSSEY OPTIONS I randomized trial	Harold Bays	2015	0.0484
7	Efficacy and safety of alirocumab in patients with heterozygous familial hypercholesterolemia and LDL-C of 160 mg/dL or higher	Henry N Ginsberg	2016	0.0482
8	Efficacy and safety of alirocumab vs ezetimibe in statin-intolerant patients, with a statin rechallenge arm: The ODYSSEY ALTERNATIVE randomized trial	Patrick M. Moriarty	2015	0.0441
9	Effect of alirocumab, a monoclonal antibody to PCSK9, on long-term cardiovascular outcomes following acute coronary syndromes: rationale and design of the ODYSSEY outcomes trial	Gregory G. Schwartz	2014	0.0432
10	Efficacy and safety of evolocumab in reducing lipids and cardiovascular events	Marc S. Sabatine	2015	0.0366

LDL-C = low-density lipoprotein cholesterol, PCSK9 = proprotein convertase subtilisin/kexin 9.